A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection.

Abstract

This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

• Authors: J Main, J L Brown, C Howells, R Galassini, M Crossey, P Karayiannis, P Georgiou, G Atkinson, H C Thomas
• Journal: Journal of viral hepatitis (J Viral Hepat) Vol. 3 Issue 4 Pg. 211-5 (Jul 1996) ISSN: 1352-0504 [Print] England
• PMID: 8871884 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiviral Agents
• DNA, Viral
• 2-Aminopurine
• Famciclovir

Topics

• 2-Aminopurine (analogs & derivatives, therapeutic use)
• Adolescent
• Adult
• Antiviral Agents (therapeutic use)
• Carrier State
• Chronic Disease
• DNA, Viral (analysis)
• Double-Blind Method
• Famciclovir
• Female
• Hepatitis B (drug therapy)
• Hepatitis B virus (genetics, physiology)
• Humans
• Male
• Middle Aged
• Virus Replication